New longer-term efficacy and safety data from pivotal Phase III ASCEMBL study for recently US-approved Scemblix (asciminib) in patients with PH+ CML-CPEarly findings from YTB323 and PHE885 CAR-T cell therapies
Investegate announcements from NOVARTIS AG CHF0.50(REGD), New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio
Novartis International AG: Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19
1
Detailed results will be submitted for publication to support scientific understanding of JAK inhibition in COVID-19 and inform ongoing research
Novartis commitment to address COVID-19 pandemic remains strong with multiple research collaboration initiatives ongoing
Basel, December 14, 2020 - Novartis today announced that the Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint
1. Initial data show there was no statistically significant reduction in the proportion of patients on ruxolitinib plus SoC therapy who experienced severe complications, including death, respiratory failure requiring mechanical ventilation or admission to the intensive care unit (ICU) by Day 29, compared to SoC alone
Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19
Phase III study did not meet its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications (death, mechanical ventilation or ICU care)
1
Detailed results will be submitted for publication to support scientific understanding of JAK inhibition in COVID-19 and inform ongoing research
Novartis commitment to address COVID-19 pandemic remains strong with multiple research collaboration initiatives ongoing
Basel, December 14, 2020 Novartis today announced that the Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint